AstraZeneca reports boost in cancer drug sales

LONDON — Anglo-Swedish drugmaker AstraZeneca is reporting its first quarterly sales in years on the back of new cancer treatments.

The company said Friday that product sales rose 4 percent in the fourth quarter to $5.49 billion, buoyed by new drugs such as bladder cancer treatment Imfinzi, and lymphoma medication Calquence.

It was the first increase since the third quarter of 2014.

AstraZeneca says it expects product sales to increase "in the low single digits" this year.

Despite encouraging news on the sales front, net income fell 29 percent to $1.3 billion. Core operating profit, which excludes restructuring and acquisition-related costs to give a better picture of underlying performance, fell 12 percent to $1.79 billion.

CEO Pascal Soriot says the sales increase shows AstraZeneca is "steadily turning a corner."

You may also interested in

Asian shares mixed as investors consider latest...

Jan 5, 2017

Asian stock indexes mixed as investors assess latest Fed meeting minutes; Japan shares slip as yen...

Choked by smog, Beijing creates new environmental...

Jan 8, 2017

Officials in Beijing have announced a new environmental police squad to root out illegal burning in...

McDonald's sells China business in deal worth up...

Jan 9, 2017

Fast-food giant McDonald's is selling a controlling stake in its China business to a group of...

Chinese delegation open to meeting Trump's team...

Jan 11, 2017

A Chinese official says President Xi Jinping's delegation to the World Economic Forum is open to...

China auto market has bumper year but 2017...

Jan 12, 2017

Industry figures show China's auto market had a bumper year in 2016 as sales grew by 15 percent,...

About Us

Frontal Report is an emerging leader in all forms of media. We aim to be the leading news brand for readers around the world.

Contact us: sales[at]frontalreport.com

Subscribe Now!